Skandinaviska Enskilda Banken (SEB)
MRSN

Skandinaviska Enskilda Banken (SEB)’s Mersana Therapeutics MRSN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,725
Closed -$306K – 970
2023
Q2 		$306K Buy
3,725
+1,386
+59% +$203K ﹤0.01% 831
2023
Q1 		$240K Sell
2,339
-114
-5% -$16K ﹤0.01% 815
2022
Q4 		$359K Buy
+2,453
New +$415K ﹤0.01% 756
2021
Q3 		– Sell
-1,212
Closed -$412K – 1066
2021
Q2 		$412K Buy
+1,212
New +$459K ﹤0.01% 904

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s MRSN Position: Q3 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 3,725 shares — an estimated $306K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in MRSN in Q2 2021 and held it in 4 quarters. The position peaked at $412K in Q2 2021. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 3,725 Mersana Therapeutics shares in Q3 2023, an estimated $306K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Mersana Therapeutics in Q2 2021 and held it in 4 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Mersana Therapeutics position peaked at $412K in Q2 2021.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2023, filed 9 Nov 2023.